<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02174419</url>
  </required_header>
  <id_info>
    <org_study_id>TR03</org_study_id>
    <secondary_id>2013-005627-17</secondary_id>
    <nct_id>NCT02174419</nct_id>
  </id_info>
  <brief_title>Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevi Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevi Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are to evaluate the effects of two doses of nalbuphine&#xD;
      HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in&#xD;
      patients with prurigo nodularis and to evaluate the safety and tolerability in the study&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
    <description>The number of subjects who reported at least a 30% reduction from baseline to Week 10, expressed as a percentage of subjects in the particular arm/group who were evaluated,</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the Evaluation Visit (Week 10) in the Mean Itch on the 0-10 Numerical Rating Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline to the Evaluation Visit (Week 10) in the Verbal Rating Scale</measure>
    <time_frame>Baseline, Week 10</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Prurigo Nodularis</condition>
  <condition>Nodularis Prurigo</condition>
  <condition>Prurigo</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 90mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER tablets 90 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine HCl ER 180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine HCl ER tablets 180 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER tablets 90 mg BID</intervention_name>
    <description>nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks</description>
    <arm_group_label>nalbuphine HCl ER 90mg</arm_group_label>
    <other_name>nalbuphine ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nalbuphine HCl ER tablets 180 mg BID</intervention_name>
    <description>nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks</description>
    <arm_group_label>nalbuphine HCl ER 180 mg</arm_group_label>
    <other_name>nalbuphine ER</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablets BID</intervention_name>
    <description>Placebo tablets BID administered for 10 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject suffering from generalized prurigo nodularis&#xD;
&#xD;
          -  Have demonstrated pruritus intensity during screening&#xD;
&#xD;
          -  Male or female who are at least 18 years old at the time of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has chronic pruritus resulting from other conditions&#xD;
&#xD;
          -  Subject has a history of substance abuse within the past year&#xD;
&#xD;
          -  Subject has a known drug allergy to opioids&#xD;
&#xD;
          -  Subject is a pregnant or lactating female&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Sciascia</last_name>
    <role>Study Director</role>
    <affiliation>Trevi Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Münster</name>
      <address>
        <city>Münster</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu</name>
      <address>
        <city>Wroclaw</city>
        <state>Dolnoslaskie</state>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 24, 2014</study_first_submitted>
  <study_first_submitted_qc>June 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <results_first_submitted>August 6, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <disposition_first_submitted>May 25, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>May 25, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 6, 2017</disposition_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Itch</keyword>
  <keyword>Chronic Itch</keyword>
  <keyword>nalbuphine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
    <mesh_term>Prurigo</mesh_term>
    <mesh_term>Neurodermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nalbuphine HCl ER 90mg</title>
          <description>nalbuphine HCl ER tablets 90 mg BID&#xD;
nalbuphine HCl ER tablets 90 mg BID: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Nalbuphine HCl ER 180 mg</title>
          <description>nalbuphine HCl ER tablets 180 mg BID&#xD;
nalbuphine HCl ER tablets 180 mg BID: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks</description>
        </group>
        <group group_id="P3">
          <title>Sugar Pill</title>
          <description>Placebo tablets BID&#xD;
Placebo tablets BID: Placebo tablets BID administered for 10 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nalbuphine HCl ER 90mg</title>
          <description>nalbuphine HCl ER tablets 90 mg BID&#xD;
nalbuphine HCl ER tablets 90 mg BID: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Nalbuphine HCl ER 180 mg</title>
          <description>nalbuphine HCl ER tablets 180 mg BID&#xD;
nalbuphine HCl ER tablets 180 mg BID: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Sugar Pill</title>
          <description>Placebo tablets BID&#xD;
Placebo tablets BID: Placebo tablets BID administered for 10 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.0" spread="8.6"/>
                    <measurement group_id="B2" value="49.1" spread="16.3"/>
                    <measurement group_id="B3" value="53.3" spread="16.7"/>
                    <measurement group_id="B4" value="52.7" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale</title>
        <description>The number of subjects who reported at least a 30% reduction from baseline to Week 10, expressed as a percentage of subjects in the particular arm/group who were evaluated,</description>
        <time_frame>Baseline, Week 10</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nalbuphine HCl ER 90mg</title>
            <description>nalbuphine HCl ER tablets 90 mg BID&#xD;
nalbuphine HCl ER tablets 90 mg BID: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Nalbuphine HCl ER 180 mg</title>
            <description>nalbuphine HCl ER tablets 180 mg BID&#xD;
nalbuphine HCl ER tablets 180 mg BID: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>Sugar Pill</title>
            <description>Placebo tablets BID&#xD;
Placebo tablets BID: Placebo tablets BID administered for 10 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the Evaluation Visit (Week 10) in Itch on the 0-10 Numerical Rating Scale</title>
          <description>The number of subjects who reported at least a 30% reduction from baseline to Week 10, expressed as a percentage of subjects in the particular arm/group who were evaluated,</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.3"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the Evaluation Visit (Week 10) in the Mean Itch on the 0-10 Numerical Rating Scale</title>
        <time_frame>Baseline, Week 10</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline to the Evaluation Visit (Week 10) in the Verbal Rating Scale</title>
        <time_frame>Baseline, Week 10</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Nalbuphine HCl ER 90mg</title>
          <description>nalbuphine HCl ER tablets 90 mg BID&#xD;
nalbuphine HCl ER tablets 90 mg BID: nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Nalbuphine HCl ER 180 mg</title>
          <description>nalbuphine HCl ER tablets 180 mg BID&#xD;
nalbuphine HCl ER tablets 180 mg BID: nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks</description>
        </group>
        <group group_id="E3">
          <title>Sugar Pill</title>
          <description>Placebo tablets BID&#xD;
Placebo tablets BID: Placebo tablets BID administered for 10 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Sciascia, MD</name_or_title>
      <organization>Trevi Therapeutics</organization>
      <phone>203-304-2499</phone>
      <email>thomas.sciascia@trevitherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

